As the pharmaceutical industry prepares for CPHI 2025, global contract development and manufacturing organization (CDMO) Kindeva is poised to showcase its comprehensive capabilities in complex drug delivery. Kindeva invites industry partners to its stand to see how it can help ensure their place as a driving force in the future of pharma.
Who is Kindeva?
Kindeva is a drug delivery CDMO with a global footprint, specializing in injectable, pulmonary, nasal and dermal drug delivery. With over 2,000 employees working across 10 manufacturing and R&D facilities worldwide, this extensive network encompasses a 1 million-square-foot current Good Manufacturing Practices (cGMP) footprint and is responsible for shipping over 100 million commercial devices annually. This operational capacity is built on a deep legacy of scientific innovation, demonstrated by a portfolio of over 1,300 patents and a history of leadership in developing groundbreaking drug delivery platforms.
A legacy of innovation:
1956: Invented the pressurized metered-dose inhaler (pMDI).
1959: Created the first emergency-use autoinjector.
1970: Invented the ComboPen® platform and launched the first drug-in-adhesive patch.
1989: Developed the breath-actuated inhaler.
1995: Launched the first CFC-free MDI.
2002: Invented the BinaJect® platform.
2005: Began development of the microneedle array patch.
2009: Created the TruJect™ platform.
2010: Developed the first commercially available dose counter for pMDIs.
2012: Invented the first CFC-free nasal MDI.
2024: Began leading the charge in the transition to next-generation, low global warming potential propellants for inhalers.
2025: Expanded sterile injectable capabilities with new Bridgeton, Missouri, facility.
2025: Completed the expansion of its Loughborough, UK, inhalation site, solidifying it as a centre of excellence for pMDI operations.
Core CDMO expertise
Kindeva provides end-to-end support across the product lifecycle, from initial concept through commercialization. Its core service areas are designed to offer integrated solutions that accelerate time to market and optimize the supply chain.
Sterile injectables: Kindeva offers a seamless integration of device manufacturing, sterile fill finish and final assembly. Its commitment to this sector is highlighted by its recent $200 million investment in its Bridgeton, Missouri, facility. This state-of-the-art, 155,000+ sq. ft. site features multiple high-speed, automated isolator lines designed for Annex 1 compliance to reduce risk and accelerate delivery.
Pulmonary: As the inventor of the pMDI, Kindeva possesses unparalleled expertise in developing and manufacturing pulmonary combination products. Its capabilities range from managing the complex interplay between formulation, device and drug product, to leading the charge in the transition to next-generation propellants (NGPs) with lower global warming potential.
Nasal: Kindeva provides full-service support for nasal administration, including the development and manufacturing of both simple and complex formulations for nasal spray devices.
Dermal: Kindeva continues to advance transdermal and intradermal delivery, from its proven drug-in-adhesive patches to next-generation systems like microneedle array patches designed to improve patient compliance and minimize systemic side effects.
Together in motion: your partner in progress
Kindeva’s operating model is built around a strategic partnership that is always moving forward and always by your side. It offers comprehensive analytical services and regulatory lifecycle management to navigate the global landscape, with support that extends much further than the next project. Clients are supported by dedicated relationship leaders to ensure full visibility and alignment, helping you to shape what’s next.
Meet with the Kindeva team at CPHI 2025, booth #5.0C8, to discover how we can step into tomorrow together. Let’s build your legacy.